Medtronic, Boston Scientific Corporation, Stryker are Dominating the Switzerland Tumor Ablation Market in 2019

Switzerland Tumor Ablation Market is expected to grow with a CAGR of 5.1% in the forecast period of 2020 to 2027. The years considered for study are as mentioned below:

Access full Reports @ https://www.databridgemarketresearch.com/reports/switzerland-tumor-ablation-market

Switzerland tumor ablation market is a highly consolidated market, which includes specific number of key players. The market has witnessed increased strategic developments owing to favourable market scenario.

The major players dealing in Switzerland tumor ablation market are introducing strong range of ablation provider along with launching new ablation and adopting strategic initiative such as acquisition, agreement, business expansion, award and recognition into the market. This helped companies to maximize the sales with enhanced product portfolio.

For instance:

  • In February 2017, Medtronic's OsteoCool(TM) RF Ablation System Receives Expanded Indication for Palliative Treatment of Metastatic Bone Tumors . This helped the company to uses targeted radiofrequency energy to ablate malignant metastatic bone tumors.

Medtronic is the dominating player in Switzerland tumor ablation market. The other key players existing in the market includes EDAP TMS, Sonacare Medical, Merit Medical Systems, HealthTronics, Inc., Misonix, INSIGHTEC, Olympus, Integra LifeSciences Corporation, Terumo Europe NV (A Subsidiary of Terumo Corporation), Abbott, Stryker, Medical Devices Business Services, Inc. and Boston Scientific Corporation, among others.

Switzerland Tumor Ablation MarketMedtronic

Medtronic’s is headquartered in Dublin, Ireland and it mainly focuses on contributing to human health by application of biomedical engineering in the research, design, manufacture and sale of instruments and appliances that elevate pain and extend life. The company has three business segments including cardiac and vascular group, minimally invasive therapies group, restoratives therapies group and diabetes group.

The company is present in Switzerland (Medtronic International Trading Sàrl). The company also has various subsidiary companies such as Cardiotron Medizintechnik G.m.b.H., Medtronic (Schweiz) A.G. / Medtronic (Suisse) S.A., Medtronic (Shanghai) Ltd, Medtronic (Thailand) Limited.

Boston Scientific Corporation

Boston Scientific Corporation is headquartered in Maryland, United States was founded in 1969. The company focuses on transforming lives to innovative medical solutions that improve the health of patients around the world. The company has wide product portfolio including access devices health, RF ablation, catheter ablation and cryoablation among others in which cryoablation, RF ablation are market focused category.

  • In March 2019, Boston Scientific Corporation announced data from the AF-FICIENT study during a late-breaking clinical trial session, the annual congress of the European Heart Rhythm Association in Lisbon, Portugal. The company actively keeps updating with the data as per requirement.

The company is present in Switzerland (Boston Scientific AG). The company also has various subsidiary companies such as American Medical Systems, LLC, Apama Medical, Inc., Boston Scientific Neuromodulation Corporation, Boston Scientific Scimed, Inc., Cardiac Pacemakers, Inc., Cosman Medical, LLC, EndoChoice, Inc., among others.

Stryker

Stryker is headquartered in New York, U.S. was founded in 1941. The company focuses on providing innovative products for orthopaedics, medical and surgical and neurotechnology and spine that helps to improve patients ad hospital outcomes. The company is engaged in providing wide range of product categories such as medical and surgical equipments, orthopaedics and neurotechnology among which medical and surgical equipment is the market focused product category.

  • In July 2017, Stryker received FDA clearance for MultiGen 2 Radiofrequency Generator. This product provides with control, efficiency, and reliability to physicians who perform tumor surgeries. This product approval paved the way for the company to make standard footprint in tumor ablation device market.

The company is present in Switzerland (Stryker Newplant AG). The company has several owned subsidiaries Ross Creek Medical, Inc.      , SpineCore, Inc., Stryker AB, Stryker Australia LLC, Stryker Australia Pty. Ltd., Stryker (Barbados) Foreign Sales Corporation, Stryker (Beijing) Healthcare Products Co. Ltd., Stryker Beteiligungs GmbH among others.